Solid Biosciences Inc. filings document regulatory disclosures for a Nasdaq-listed precision genetic medicine company developing gene therapies for rare neuromuscular and cardiac diseases. Its SEC records include Form 8-K reports on operating and financial results, Regulation FD presentations, clinical updates for SGT-003 and the INSPIRE DUCHENNE trial, material agreements, and capital-structure matters.
Proxy filings describe annual stockholder meeting proposals, board classification matters, advisory votes, executive compensation, and equity awards. The filing record also identifies the company’s common stock as listed on The Nasdaq Global Select Market under the SLDB symbol.
Solid Biosciences Inc. (SLDB) is the subject of a Schedule 13G in which RTW Investments, LP and its Managing Partner and Chief Investment Officer, Roderick Wong, each report beneficial ownership of 5,905,426 common shares, or 5.5% of the class. Both report shared voting and dispositive power over those shares and no sole voting or dispositive power. The shares are held directly by funds advised by RTW Investments; those funds have the right to receive, or direct receipt of, dividends and sale proceeds. The percentage is based on 107,225,238 shares outstanding as of August 4, 2026.
Solid Biosciences Inc. reports that RA Capital Management, L.P., Peter Kolchinsky and Rajeev Shah each beneficially own 12,036,126 shares, or 10.8% of the common stock; RA Capital Healthcare Fund, L.P. reports 11,897,896 shares, or 10.7%. The amendment says the reported ownership change reflects dilution, not an acquisition or disposition by the reporting persons. The percentages are based on 111,610,531 shares outstanding as of October 30, 2026.
The Fund directly holds pre-funded warrants exercisable for up to 8,178,412 shares. The warrants are currently blocked from exercise because the Fund, together with affiliates and other attribution parties, would exceed the 9.99% beneficial ownership limit after exercise.
Solid Biosciences Inc. reported a third-quarter 2026 net loss of $53.9 million, versus $45.8 million a year earlier; nine-month net loss was $165.5 million versus $124.5 million. Third-quarter research and development expense was $43.6 million, up from $38.9 million, and general and administrative expense was $14.1 million versus $9.2 million.
As of September 30, 2026, cash, cash equivalents and available-for-sale securities totaled $348.9 million, excluding $1.3 million of restricted cash; the company expects these resources to fund operating expenses and capital expenditures into the first half of 2028. Operating activities used $145.4 million of cash in the first nine months of 2026, versus $102.7 million in 2025. Funding included approximately $226.3 million of net proceeds from the March 2026 private placement and $76.5 million from ATM sales during the nine-month period. The company expects operating losses to continue for the foreseeable future.
As of November 3, 2026, 53 participants had been dosed in the SGT-003 Phase 1/2 trial, with two previously disclosed treatment-related serious adverse events. Five participants had been dosed in the SGT-212 Phase 1b FALCON trial, with no treatment-related serious adverse events observed; initial data are anticipated in the first quarter of 2027, subject to enrollment.
Solid Biosciences Inc. (SLDB) director Ilan Ganot reported an indirect award of 150,000 restricted stock units held by his wife on October 1, 2026. Each unit represents a contingent right to receive one share of common stock. The RSUs vest in full on October 1, 2029, subject to Ms. Ganot's continued service through that date; 150,000 RSUs were reported following the award.
Solid Biosciences Inc. Chief Medical Officer Gabriel Brooks converted 9,750 restricted stock units into 9,750 common shares on October 18, 2026. On October 19, he sold 4,374 shares at $5.62 per share to cover withholding taxes following RSU vesting. The sale was not discretionary; it followed a durable automatic sale instruction letter adopted August 15, 2024, and was reported under a Rule 10b5-1 plan.
Solid Biosciences Inc. director Ian F. Smith converted 3,440 restricted stock units into 3,440 shares of common stock on October 2, 2026. The units convert one-for-one; after the transaction, Smith held 141,585 common shares directly. The units were granted January 2, 2026 and vested in equal quarterly installments beginning three months after the grant, with the final installment vesting 12 months after the grant.
Perceptive Advisors LLC, together with related entities and Joseph Edelman, reports beneficial ownership of 12,046,579 shares of Solid Biosciences Inc. common stock, representing 11.2% of the class. This percentage is based on 107,365,171 shares of common stock, including 139,933 shares issuable upon vested options held by Adam Stone.
The holding is primarily through Perceptive Life Sciences Master Fund, Ltd., which directly holds 11,833,539 common shares and 8,912,655 pre-funded warrants exercisable at $0.001 per share, subject to a 9.99% Beneficial Ownership Limitation that currently prevents any warrant exercise. Perceptive Xontogeny Venture Fund, LP directly holds 73,107 shares. Adam Stone holds options for 217,433 shares, of which 139,933 are exercisable within 60 days; the Master Fund is entitled to receive director compensation from his board service via a management fee offset.
Vestal Point Capital, LP and its Chief Investment Officer, Ryan Wilder, report beneficial ownership of Solid Biosciences Inc. common stock through a fund and a managed account they advise. Their position totals 4,833,796 shares of common stock, including shares issuable upon exercise of pre-funded common stock purchase warrants.
The reported holdings represent 4.8% of Solid Biosciences’ common stock, based on 98,449,606 shares outstanding as of May 8, 2026, and assuming exercise of the warrants. Voting and dispositive power over all reported shares is shared, with no sole voting or dispositive power reported. The filers state that the filing should not be construed as an admission of beneficial ownership for all purposes.
Solid Biosciences Inc. filed a prospectus supplement on August 6, 2026 under its universal shelf registration statement on Form S-3 (File No. 333-287325), covering the offer and sale of up to $200.0 million of common stock pursuant to an Amended and Restated Sales Agreement with Jefferies LLC.
This new supplement follows a prior prospectus supplement under a different Form S-3 that permitted up to $85.0 million of common stock sales; as of the new filing, the company has issued and sold shares for aggregate gross proceeds of approximately $85.0 million under that earlier capacity and will no longer use it for additional sales. A legal opinion from Wilmer Cutler Pickering Hale and Dorr LLP regarding the shares is filed as Exhibit 5.1, and offerings will be made only by means of the new prospectus supplement and base prospectus.
Solid Biosciences Inc. is registering an at-the-market offering of up to $200,000,000 of common stock under an amended sales agreement with Jefferies LLC, which will act as sales agent and receive up to 3.0% of the gross sales price as commission. Sales may be made from time to time through The Nasdaq Global Select Market or other permitted methods deemed an at-the-market offering under Rule 415(a)(4). Shares outstanding were 105,125,366 as of June 30, 2026, and an illustrative dilution calculation using a price of $8.73 per share shows net tangible book value per share rising from $3.56 to $4.43, with dilution of $4.30 per share to new investors if the full $200.0 million is sold. The company plans to use any net proceeds for general corporate purposes, including research and development, preclinical and clinical work, potential acquisitions or in-licenses, debt repayment or refinancing, working capital and capital expenditures.